REGN
Regeneron Pharmaceuticals Inc (REGN) Dupixent (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) FY 2026 Other Release
Regeneron Pharmaceuticals Inc (REGN) Regeneron Renews Sponsorship of the Regeneron Science Talent Search Through 2036, Committing an Additional $150 Million to Empower the Next Generation of Science and Technology Leaders
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) FY 2026 Other Release
Regeneron Pharmaceuticals Inc (REGN) Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS)
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) FY 2026 Other Release
Regeneron Pharmaceuticals Inc (REGN) Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) FY 2026 Other Release
Regeneron Pharmaceuticals Inc (REGN) Q4 2025 Earnings Call
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) Q4 2025 Earnings Conference
Regeneron Pharmaceuticals Inc (REGN) Leerink Partners 2026 Global Healthcare Conference
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) FY 2026 Corporate Conference
Regeneron Pharmaceuticals Inc (REGN) TD Cowen 46th Annual Health Care Conference
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) FY 2026 Corporate Conference
Regeneron Pharmaceuticals Inc (REGN) Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) FY 2026 Other Release